Invitae Stock Jumps As Higher Test Volume More Than Doubles Q2 Topline, Raises FY21 Sales Outlook
Invitae Corporation (NYSE:NVTA), after the close of the market on Tuesday, reported its second-quarter revenues of $116.3 million, +152% Y/Y,…
Benchmark Upgrades Invitae to Buy, Announces $35 Price Target
Benchmark analyst Bruce Jackson upgrades Invitae (NYSE:NVTA) from Hold to Buy and announces $35 price target.
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
14 Stocks Moving In Tuesday’s After-Hours Session
RingCentral (NYSE: RNG) shares are trading higher after the company reported better-than-expected Q2 EPS and sales results and issued Q3 and FY21 EPS and sales guidance above estimates.
Invitae Q2 Adj. EPS $(0.85) Misses $(0.65) Estimate, Sales $116.30M Beat $108.30M Estimate; Raises Guidance
Invitae (NYSE:NVTA) reported quarterly losses of $(0.85) per share which missed the analyst consensus estimate of $(0.65) by 30.77 percent. This is a 10.39 percent decrease over losses of $(0.77) per share from the same
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly’s Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 2)
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.